(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

• Status: Completed
• Trial end date: 2021-09-15
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Blueprint Medicines Corporation

Criteria

Inclusion Criteria:

1. Patients who are ≥ 18 years of age.

2. Patients who have histologically confirmed metastatic or unresectable GIST.

3. Patients who received imatinib and 1 or 2 other TKIs as prior treatment regimens. Patients who experienced intolerance to prior therapies must have objective disease progression prior to enrollment onto BLU-285-1303 study.

4. Patients who have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.

Exclusion Criteria:

1. Patients who have received prior treatment with avapritinib or regorafenib.

2. Patients who have previously received more than 3 different TKI treatment regimens.

3. Patients who are known to be both V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and platelet-derived growth factor receptor alpha (PDGRFα) wild type.

4. Patients who received any systemic anticancer therapy within 1 week before the first dose of study drug.

5. Patients who have clinically significant cardiovascular disease

6. Patients have experienced arterial thrombotic or embolic events within 6 months before the first dose of study drug, or venous thrombotic events within 14 days of the first dose of study drug

7. Patients who have experienced any hemorrhage or bleeding event NCI CTCAE version 5.0 Grade 3 or higher within 4 weeks before the first dose of study drug

8. Patients who have a known risk of intracranial bleeding, or a history of intracranial bleeding within 1 year prior to the first dose of study drug

9. Patients who have a symptomatic non-healing wound, ulcer, gastrointestinal perforation, or bone fracture.

10. Patients who have poor organ function as defined by laboratory parameters specified in the protocol.

11. Patients who have received neutrophil growth factor support within 14 days of first dose of study drug.

12. Patients who require therapy with a concomitant medication that is a strong inhibitor or strong inducer of CYP3A4.

13. Patients who have had a major surgical procedure within 14 days of the first dose of study drug. Patient has significant traumatic injury within 28 days before the first dose of study drug.

14. Patients who have a history of another primary malignancy that has been diagnosed or required therapy within 3 years before first dose of study drug.

15. Patients who have a history of a seizure disorder requiring anti-seizure medication.

16. Patients who have metastases to the brain.

17. Patients who have a QT interval corrected using Fridericia's formula (QTcF) of > 450 msec.

18. Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of the first dose of study drug and for at least 60 days after the last dose of study drug. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of the first dose of study drug and for at least 90 days after the last dose of study drug.

19. Women who are pregnant.

20. Women who are breastfeeding.

21. Patients who have prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality as determined by the investigator.